Name: Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics, Diagnostics), Disease (Infectious, Gastrointestinal), Route (Oral, Rectal), CDMO (Formulation, Strain Engineering), Type (BCT/FMT, Live Bacteria) - Global Forecast to 2031
Brand: MarketsandMarkets
SKU: BT2711
Price: 4950 USD
Availability: InStock

1 INTRODUCTION 34 1.1 STUDY OBJECTIVES 34 1.2 MARKET DEFINITION 34 1.3 STUDY SCOPE 35 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 35 1.3.2 INCLUSIONS AND EXCLUSIONS 36 1.3.3 YEARS CONSIDERED 36 1.4 CURRENCY CONSIDERED 36 1.5 STAKEHOLDERS 37 1.6 SUMMARY OF CHANGES 37 2 RESEARCH METHODOLOGY 38 2.1 RESEARCH DATA 38 2.1.1 SECONDARY DATA 39 2.1.2 PRIMARY DATA 40 2.2 MARKET SIZE ESTIMATION METHODOLOGY 41 2.2.1 INSIGHTS FROM PRIMARY EXPERTS 43 2.2.2 SEGMENTAL MARKET SIZE ESTIMATION 44 2.3 GROWTH RATE PROJECTIONS 45 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 47 2.5 RESEARCH ASSUMPTIONS 47 2.6 RESEARCH LIMITATIONS 48 2.7 RISK ANALYSIS 48 3 EXECUTIVE SUMMARY 49 4 PREMIUM INSIGHTS 54 4.1 HUMAN MICROBIOME MARKET OVERVIEW 54 4.2 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY TYPE AND COUNTRY, 2024 55 4.3 HUMAN MICROBIOME MARKET, BY TYPE, 2025 VS. 2031 55 4.4 HUMAN MICROBIOME MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 56 4.5 HUMAN MICROBIOME MARKET, BY END USER, 2025 56 5 MARKET OVERVIEW 57 5.1 INTRODUCTION 57 5.2 MARKET DYNAMICS 57 5.2.1 DRIVERS 58 5.2.1.1 Collaborative initiatives between organizations and academia 58 5.2.1.2 Increasing number of startups/SMEs exploring microbiome 60 5.2.1.3 Advancements in microbiome sequencing 62 5.2.2 RESTRAINTS 62 5.2.2.1 Complex regulatory policies 62 5.2.2.2 High investments in commercializing microbiome drugs 64 5.2.3 OPPORTUNITIES 64 5.2.3.1 Increasing demand for personalized medicines 64 5.2.3.2 Emergence of postbiotics 65 5.2.4 CHALLENGES 65 5.2.4.1 Slow patient adoption of microbiome-based therapies 65 5.2.4.2 Complexities in developing microbiome therapies 66 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 66 5.3.1 DISRUPTION INDEX: MARKET READINESS VS. ADOPTION VS. MATURITY 67 5.3.1.1 Market readiness 68 5.3.1.2 Adoption 68 5.3.1.3 Maturity 68 5.4 PRICING ANALYSIS 69 5.4.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022–2024 71 5.4.2 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2022–2024 73 5.5 VALUE CHAIN ANALYSIS 75 5.5.1 HUMAN MICROBIOME DRUGS 75 5.5.2 HUMAN MICROBIOME SUPPLEMENTS 76 5.5.3 HUMAN MICROBIOME DIAGNOSTICS 77 5.6 ECOSYSTEM ANALYSIS 78 5.6.1 ECOSYSTEM SHIFT 79 5.6.1.1 Specialized raw material and data suppliers 79 5.6.1.2 Hot-bet innovator startups 80 5.6.1.3 Integrated end users and prosumer models 80 5.6.1.4 Regulatory and quality assurance orchestrators 80 5.6.1.5 Diagnostics-driven personalization 81 5.6.1.6 Microbiome-as-a-Service (Maas) 81 5.6.2 EMERGING BUSINESS MODELS 81 5.6.2.1 Emerging B2C model 81 5.6.2.2 Personalized supplements model 81 5.6.3 INTERCONNECTED MARKET DYNAMICS 82 5.7 INVESTMENT AND FUNDING SCENARIO 82 5.7.1 MAJOR INVESTMENTS AND FUNDING BY KEY MARKET PLAYERS 83 5.7.2 OTHER INVESTMENTS AND FUNDING 86 5.8 TECHNOLOGY ANALYSIS 88 5.8.1 KEY TECHNOLOGIES 88 5.8.1.1 Whole-genome sequencing 88 5.8.1.2 16s RNA sequencing method 88 5.8.1.3 Nanopore sequencing 88 5.8.2 COMPLEMENTARY TECHNOLOGIES 89 5.8.2.1 Metatranscriptomics 89 5.8.2.2 Metagenomics 89 5.8.2.3 Metabolomics 90 5.8.3 ADJACENT TECHNOLOGIES 90 5.8.3.1 Sample preparation 90 5.8.3.2 Data analysis 91 5.8.3.3 Library synthesis 91 5.9 PATENT ANALYSIS 92 5.10 KEY CONFERENCES AND EVENTS, 2025–2026 95 5.11 CASE STUDY ANALYSIS 96 5.11.1 EFFECT OF REBYOTA ON QUALITY OF LIFE IN PATIENTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION 96 5.11.2 ECOSPOR IV STUDY OF VOWST FOR CLOSTRIDIOIDES DIFFICILE INFECTION 96 5.11.3 DELONG#3 STUDY FOR QUALITY OF LIFE IMPROVEMENT BY VSL#3 PROBIOTIC IN POST-COVID-19 PATIENTS 97 5.12 TARIFF AND REGULATORY ANALYSIS 97 5.12.1 TARIFF DATA (HS CODE 3002.90) 97 5.12.2 REGULATORY LANDSCAPE 98 5.12.2.1 North America 98 5.12.2.1.1 US 98 5.12.2.1.2 Canada 99 5.12.2.2 Europe 99 5.12.2.2.1 UK 100 5.12.2.3 Asia Pacific 101 5.12.2.3.1 China 101 5.12.2.3.2 Japan 101 5.12.2.3.3 South Korea 102 5.12.2.3.4 Australia 102 5.12.2.3.5 Rest of Asia Pacific 103 5.12.3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103 5.13 PORTER’S FIVE FORCES ANALYSIS 107 5.13.1 BARGAINING POWER OF SUPPLIERS 108 5.13.2 BARGAINING POWER OF BUYERS 108 5.13.3 THREAT OF NEW ENTRANTS 109 5.13.4 THREAT OF SUBSTITUTES 109 5.13.5 INTENSITY OF COMPETITIVE RIVALRY 109 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 110 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 110 5.14.2 BUYING CRITERIA 111 5.15 PIPELINE ANALYSIS 112 5.16 IMPACT OF AI/GEN AI ON HUMAN MICROBIOME MARKET 114 5.16.1 INTRODUCTION 114 5.16.2 MARKET POTENTIAL OF AI IN HUMAN MICROBIOME MARKET 114 5.16.3 AI USE CASES 115 5.16.4 KEY PLAYERS IMPLEMENTING AI 115 5.16.5 FUTURE OF GENERATIVE AI IN HUMAN MICROBIOME MARKET 116 5.17 IMPACT OF US TARIFF ON HUMAN MICROBIOME MARKET 117 5.17.1 KEY TARIFF RATES 117 5.17.2 PRICE IMPACT ANALYSIS 118 5.17.3 KEY IMPACT ON COUNTRY/REGION 119 5.17.3.1 US 119 5.17.3.2 Europe 119 5.17.3.3 Asia Pacific 120 5.17.3.4 Rest of the World 120 5.17.4 IMPACT ON END-USE INDUSTRY 120 5.17.4.1 Hospitals and clinics 120 5.17.4.2 Long-term care facilities 121 5.18 MANAGING GLP-1 SIDE EFFECTS WITH MICROBIOME INTERVENTIONS 121 5.19 FUTURE TRENDS IN HUMAN MICROBIOME MARKET 122 5.19.1 TYPE 122 5.19.2 DISEASE 122 5.19.3 END USER 123 6 HUMAN MICROBIOME MARKET, BY PRODUCT 124 6.1 INTRODUCTION 125 6.2 DRUGS 125 6.2.1 GROWING PIPELINE OF MICROBIOME-BASED DRUGS IN LATE-STAGE CLINICAL TRIALS TO DRIVE MARKET 125 6.3 SUPPLEMENTS 129 6.3.1 PROBIOTICS 132 6.3.1.1 Increasing consumer awareness about probiotics for improved gut health and immunity to aid growth 132 6.3.2 PREBIOTICS 135 6.3.2.1 Rising development of targeted prebiotics to expedite growth 135 6.3.3 SYNBIOTICS 138 6.3.3.1 Growing demand for personalized treatment and rising incidence of dysbiosis to fuel market 138 6.4 DIAGNOSTICS 141 6.4.1 INCREASING PRODUCT LAUNCHES AND TECHNOLOGY TRANSFER TO FACILITATE GROWTH 141 7 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE 145 7.1 INTRODUCTION 146 7.2 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT) 146 7.2.1 ADVANCEMENTS IN CLINICAL TRIALS FOR TREATMENT OF C. DIFFICILE INFECTION TO AUGMENT GROWTH 146 7.3 LIVE BACTERIA PRODUCTS (LBP) 148 7.3.1 INCREASING CONSUMER FOCUS ON PREVENTIVE HEALTH TO AID GROWTH 148 7.4 OTHER MICROBIOME TYPES 151 8 HUMAN MICROBIOME MARKET, BY DISEASE 155 8.1 INTRODUCTION 156 8.2 INFECTIOUS DISEASES 156 8.2.1 EMERGENCE OF MULTIDRUG-RESISTANT BACTERIA TO FOSTER GROWTH 156 8.3 GASTROINTESTINAL DISEASES 159 8.3.1 INCREASING DEMAND FOR PERSONALIZED THERAPIES TO AID GROWTH 159 8.4 ENDOCRINE & METABOLIC DISORDERS 162 8.4.1 DEVELOPMENT OF MICROBIOME MODULATORS FOR METABOLIC DISORDERS TO BOOST MARKET 162 8.5 OTHER DISEASES 165 9 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION 169 9.1 INTRODUCTION 170 9.2 ORAL ROUTE OF ADMINISTRATION 170 9.2.1 WIDESPREAD PATIENT ACCEPTANCE AND EXTENSIVE PRODUCT OFFERINGS TO ENCOURAGE GROWTH 170 9.3 RECTAL ROUTE OF ADMINISTRATION 173 9.3.1 ABILITY TO RESTORE HEALTHY GUT TO FACILITATE GROWTH 173 10 HUMAN MICROBIOME MANUFACTURING MARKET, BY SERVICE 176 10.1 INTRODUCTION 177 10.2 STRAIN DEVELOPMENT & OPTIMIZATION 177 10.2.1 RISING DEMAND FOR TARGETED, STRAIN-SPECIFIC MICROBIOME THERAPIES TO BOOST MARKET 177 10.3 FERMENTATION & DOWNSTREAM PROCESSING 178 10.3.1 GROWING DEMAND FOR CLINICAL-STAGE BIOTHERAPEUTICS TO DRIVE MARKET 178 10.4 FORMULATION & FILL/FINISH 178 10.4.1 INCREASING STUDIES ON LIVE BIOTHERAPEUTIC PRODUCTS TO PROMOTE GROWTH 178 10.5 OTHER SERVICES 178 11 HUMAN MICROBIOME MARKET, BY END USER 180 11.1 INTRODUCTION 181 11.2 HOSPITALS & CLINICS 181 11.2.1 AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE AND EXPERTISE TO AUGMENT GROWTH 181 11.3 LONG-TERM CARE FACILITIES 184 11.3.1 NEED FOR SPECIALIZED CARE AND CONTINUOUS MONITORING FOR PATIENTS WITH CHRONIC HEALTH CONDITIONS TO DRIVE MARKET 184 11.4 OTHER END USERS 187 12 HUMAN MICROBIOME MARKET, BY REGION 191 12.1 INTRODUCTION 192 12.2 NORTH AMERICA 192 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 195 12.2.2 US 196 12.2.2.1 Favorable government initiatives and booming diagnostics sector to drive market 196 12.2.3 CANADA 199 12.2.3.1 Increasing prevalence of chronic diseases to expedite growth 199 12.3 EUROPE 201 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 204 12.3.2 GERMANY 205 12.3.2.1 Rapid increase in government and private funding to propel market 205 12.3.3 UK 208 12.3.3.1 Significant government investments in microbiome research and presence of microbiome companies to propel growth 208 12.3.4 FRANCE 210 12.3.4.1 Growing focus on developing new products and services using microbiome data to boost market 210 12.3.5 ITALY 213 12.3.5.1 Rise in research activities to encourage growth 213 12.3.6 SPAIN 216 12.3.6.1 Favorable microbiome research landscape to support growth 216 12.3.7 REST OF EUROPE 219 12.4 ASIA PACIFIC 221 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 225 12.4.2 CHINA 226 12.4.2.1 Rapidly expanding healthcare industry to accelerate growth 226 12.4.3 JAPAN 229 12.4.3.1 Booming geriatric population to contribute to growth 229 12.4.4 INDIA 231 12.4.4.1 Increasing number of human microbiome diagnostic companies to augment growth 231 12.4.5 SOUTH KOREA 234 12.4.5.1 Booming bio-health market to advance growth 234 12.4.6 AUSTRALIA 237 12.4.6.1 Growing number of product approvals to boost markt 237 12.4.7 REST OF ASIA PACIFIC 239 12.5 LATIN AMERICA 242 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 244 12.5.2 BRAZIL 245 12.5.2.1 Rising probiotics demand to drive market 245 12.5.3 REST OF LATIN AMERICA 247 12.6 MIDDLE EAST 249 12.6.1 MACROECONOMIC OUTLOOK IN MIDDLE EAST 252 12.6.2 GCC COUNTRIES 253 12.6.2.1 Saudi Arabia 255 12.6.2.1.1 Growing focus on healthcare infrastructure to fuel market 255 12.6.2.2 UAE 258 12.6.2.2.1 Increasing focus on immunotherapy and biotechnology to augment growth 258 12.6.2.3 Rest of GCC countries 260 12.6.3 REST OF MIDDLE EAST 263 12.7 AFRICA 265 12.7.1 INCREASING STUDIES AND INITIATIVES ON MICROBIOME TO PROMOTE GROWTH 265 12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 267 13 COMPETITIVE LANDSCAPE 269 13.1 INTRODUCTION 269 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 269 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMAN MICROBIOME MARKET 269 13.3 REVENUE ANALYSIS, 2022–2024 272 13.4 MARKET SHARE ANALYSIS, 2024 273 13.5 COMPANY VALUATION AND FINANCIAL METRICS 276 13.6 BRAND/PRODUCT COMPARISON 277 13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 279 13.7.1 STARS 279 13.7.2 EMERGING LEADERS 279 13.7.3 PERVASIVE PLAYERS 279 13.7.4 PARTICIPANTS 279 13.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 281 13.7.5.1 Company footprint 281 13.7.5.2 Region footprint 282 13.7.5.3 Product footprint 283 13.7.5.4 Type footprint 284 13.7.5.5 Disease footprint 285 13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 286 13.8.1 PROGRESSIVE COMPANIES 286 13.8.2 RESPONSIVE COMPANIES 286 13.8.3 DYNAMIC COMPANIES 286 13.8.4 STARTING BLOCKS 286 13.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 288 13.8.5.1 Detailed list of key startups/SMEs 288 13.8.5.2 Competitive benchmarking of key emerging players/startups 289 13.9 COMPETITIVE SCENARIO 290 13.9.1 PRODUCT LAUNCHES AND APPROVALS 290 13.9.2 DEALS 291 13.9.3 EXPANSIONS 292 14 COMPANY PROFILES 294 14.1 KEY PLAYERS 294 14.1.1 INTERNATIONAL FLAVORS & FRAGRANCES INC. 294 14.1.1.1 Business overview 294 14.1.1.2 Products offered 295 14.1.1.3 Recent developments 297 14.1.1.3.1 Deals 297 14.1.1.3.2 Expansions 298 14.1.1.4 MnM view 298 14.1.1.4.1 Key strengths 298 14.1.1.4.2 Strategic choices 298 14.1.1.4.3 Weaknesses and competitive threats 299 14.1.2 SEED HEALTH, INC. 300 14.1.2.1 Business overview 300 14.1.2.2 Products offered 300 14.1.2.3 Recent developments 301 14.1.2.3.1 Product launches and approvals 301 14.1.2.3.2 Deals 302 14.1.2.3.3 Expansions 302 14.1.2.4 MnM view 303 14.1.2.4.1 Key strengths 303 14.1.2.4.2 Strategic choices 303 14.1.2.4.3 Weaknesses and competitive threats 303 14.1.3 SERES THERAPEUTICS 304 14.1.3.1 Business overview 304 14.1.3.2 Products offered 305 14.1.3.3 Recent developments 305 14.1.3.3.1 Product launches and approvals 305 14.1.3.3.2 Deals 306 14.1.3.4 MnM view 306 14.1.3.4.1 Key strengths 306 14.1.3.4.2 Strategic choices 306 14.1.3.4.3 Weaknesses and competitive threats 307 14.1.4 FERRING B.V. 308 14.1.4.1 Business overview 308 14.1.4.2 Products offered 309 14.1.4.3 Recent developments 310 14.1.4.3.1 Product launches and approvals 310 14.1.4.3.2 Deals 310 14.1.4.4 MnM view 311 14.1.4.4.1 Key strengths 311 14.1.4.4.2 Strategic choices 311 14.1.4.4.3 Weaknesses and competitive threats 311 14.1.5 PENDULUM 312 14.1.5.1 Business overview 312 14.1.5.2 Products offered 312 14.1.5.3 Recent developments 313 14.1.5.3.1 Product launches and approvals 313 14.1.5.3.2 Deals 313 14.1.5.4 MnM view 314 14.1.5.4.1 Key strengths 314 14.1.5.4.2 Strategic choices 314 14.1.5.4.3 Weaknesses and competitive threats 314 14.1.6 OPTIBIOTIX HEALTH PLC 315 14.1.6.1 Business overview 315 14.1.6.2 Products offered 316 14.1.6.3 Recent developments 317 14.1.6.3.1 Product launches and approvals 317 14.1.6.3.2 Deals 318 14.1.7 BIOGAIA 319 14.1.7.1 Business overview 319 14.1.7.2 Products offered 320 14.1.7.3 Recent developments 321 14.1.7.3.1 Product launches and approvals 321 14.1.7.3.2 Deals 321 14.1.7.3.3 Expansions 322 14.1.8 MAAT PHARMA 323 14.1.8.1 Business overview 323 14.1.8.2 Products offered 324 14.1.8.3 Recent developments 324 14.1.8.3.1 Deals 324 14.1.8.3.2 Other developments 325 14.1.9 MICROBA 326 14.1.9.1 Business overview 326 14.1.9.2 Products offered 327 14.1.9.3 Recent developments 327 14.1.9.3.1 Product launches and approvals 327 14.1.10 BIOMEBANK 328 14.1.10.1 Business overview 328 14.1.10.2 Products offered 328 14.1.10.3 Recent developments 329 14.1.10.3.1 Product launches and approvals 329 14.1.10.3.2 Deals 329 14.1.10.3.3 Expansions 329 14.1.11 BIOHM HEALTH 330 14.1.11.1 Business overview 330 14.1.11.2 Products offered 330 14.1.11.3 Recent developments 332 14.1.11.3.1 Deals 332 14.1.12 ACTIAL FARMACEUTICA SRL 334 14.1.12.1 Business overview 334 14.1.12.2 Products offered 334 14.1.13 RESBIOTIC 335 14.1.13.1 Business overview 335 14.1.13.2 Products offered 335 14.1.13.3 Recent developments 336 14.1.13.3.1 Product launches and approvals 336 14.1.13.3.2 Deals 336 14.1.13.3.3 Expansions 337 14.1.14 INFINANT HEALTH INC. 338 14.1.14.1 Business overview 338 14.1.14.2 Products offered 338 14.1.14.3 Recent developments 339 14.1.14.3.1 Deals 339 14.1.15 EXEGI PHARMA 340 14.1.15.1 Business overview 340 14.1.15.2 Products offered 340 14.1.15.3 Recent developments 341 14.1.15.3.1 Deals 341 14.1.16 FINCH THERAPEUTICS GROUP, INC. 342 14.1.16.1 Business overview 342 14.1.16.2 Products offered 343 14.1.16.3 Recent developments 343 14.1.16.3.1 Deals 343 14.1.17 INFANT BACTERIAL THERAPEUTICS AB 344 14.1.17.1 Business overview 344 14.1.17.2 Products offered 344 14.1.18 VIOME LIFESCIENCES 346 14.1.18.1 Business overview 346 14.1.18.2 Products offered 346 14.1.18.3 Recent developments 347 14.1.18.3.1 Product launches and approvals 347 14.1.19 GENOVA DIAGNOSTICS 348 14.1.19.1 Business overview 348 14.1.19.2 Products offered 348 14.2 OTHER PLAYERS 349 14.2.1 AOBIOME 349 14.2.2 GUANGZHOU ZHIYI BIOTECHNOLOGY CO., LTD. 350 14.2.3 NUBIYOTA 351 14.2.4 OXTHERA 352 14.2.5 NEXBIOME 353 14.2.6 VEDANTA BIOSCIENCES, INC. 354 14.2.7 ENTEROME 355 14.2.8 APSEN FARMACÊUTICA 356 14.2.9 METAGEN, INC. 357 14.2.10 SNIPR BIOME 358 14.2.11 MIKROBIOMIK 359 14.2.12 SYNLOGIC 360 14.2.13 GENETIC ANALYSIS 361 14.2.14 METABIOMICS 361 14.2.15 SUN GENOMICS, INC. 362 15 APPENDIX 363 15.1 DISCUSSION GUIDE 363 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 367 15.3 CUSTOMIZATION OPTIONS 369 15.4 RELATED REPORTS 369 15.5 AUTHOR DETAILS 370

TABLE 1 HUMAN MICROBIOME MARKET: INCLUSIONS AND EXCLUSIONS 36 TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 46 TABLE 3 HUMAN MICROBIOME MARKET: RISK ANALYSIS 48 TABLE 4 HUMAN MICROBIOME MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 58 TABLE 5 INDUSTRY COLLABORATIONS IN HUMAN MICROBIOME MARKET, 2022–2024 59 TABLE 6 LIST OF STARTUPS/SMES IN HUMAN MICROBIOME MARKET 61 TABLE 7 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022–2024 (USD) 71 TABLE 8 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2022–2024 (USD) 73 TABLE 9 HUMAN MICROBIOME MARKET: MAJOR INVESTMENT AND FUNDING, 2022–2024 83 TABLE 10 HUMAN MICROBIOME MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2023–2024 93 TABLE 11 HUMAN MICROBIOME MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 95 TABLE 12 TARIFF DATA FOR HS CODE 3002.90 98 TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103 TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 104 TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 104 TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105 TABLE 17 REGULATORY LANDSCAPE OF LIVE BIOTHERAPEUTIC PRODUCTS 106 TABLE 18 HUMAN MICROBIOME MARKET: PORTER’S FIVE FORCES ANALYSIS 107 TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%) 110 TABLE 20 KEY BUYING CRITERIA, BY END USER 111 TABLE 21 KEY PLAYERS IMPLEMENTING AI IN HUMAN MICROBIOME 115 TABLE 22 COMPANIES LEVERAGING AI IN HUMAN MICROBIOME MARKET 116 TABLE 23 US-ADJUSTED RECIPROCAL TARIFF RATES 117 TABLE 24 KEY PRODUCT-RELATED TARIFF: PHARMACEUTICAL PRODUCTS, MISCELLANEOUS EDIBLE PREPARATIONS, AND PRODUCTS OF ANIMAL ORIGIN 118 TABLE 25 CRITICAL COMPONENTS EXPOSED TO TARIFF CHANGES 119 TABLE 26 HUMAN MICROBIOME SUPPLEMENTS POSITIONED AS GLP-1 SUPPORT 121 TABLE 27 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 125 TABLE 28 HUMAN MICROBIOME DRUGS IN CLINICAL STAGE 126 TABLE 29 HUMAN MICROBIOME DRUGS MARKET, BY REGION, 2023–2031 (USD MILLION) 128 TABLE 30 NORTH AMERICA: HUMAN MICROBIOME DRUGS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 128 TABLE 31 ASIA PACIFIC: HUMAN MICROBIOME DRUGS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 129 TABLE 32 HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 129 TABLE 33 HUMAN MICROBIOME SUPPLEMENTS MARKET, BY REGION, 2023–2031 (USD MILLION) 130 TABLE 34 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 130 TABLE 35 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 130 TABLE 36 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 131 TABLE 37 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 131 TABLE 38 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY REGION, 2023–2031 (USD MILLION) 131 TABLE 39 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 132 TABLE 40 HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY REGION, 2023–2031 (USD MILLION) 133 TABLE 41 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION) 133 TABLE 42 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION) 133 TABLE 43 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION) 134 TABLE 44 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION) 134 TABLE 45 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY REGION, 2023–2031 (USD MILLION) 134 TABLE 46 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION) 135 TABLE 47 HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY REGION, 2023–2031 (USD MILLION) 136 TABLE 48 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION) 136 TABLE 49 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION) 136 TABLE 50 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION) 137 TABLE 51 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION) 137 TABLE 52 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY REGION, 2023–2031 (USD MILLION) 137 TABLE 53 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION) 138 TABLE 54 HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY REGION, 2023–2031 (USD MILLION) 139 TABLE 55 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION) 139 TABLE 56 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION) 139 TABLE 57 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION) 140 TABLE 58 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION) 140 TABLE 59 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY REGION, 2023–2031 (USD MILLION) 140 TABLE 60 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION) 141 TABLE 61 HUMAN MICROBIOME DIAGNOSTICS MARKET, BY REGION, 2023–2031 (USD MILLION) 142 TABLE 62 NORTH AMERICA: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 142 TABLE 63 EUROPE: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 142 TABLE 64 ASIA PACIFIC: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 143 TABLE 65 LATIN AMERICA: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 143 TABLE 66 MIDDLE EAST: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY REGION, 2023–2031 (USD MILLION) 143 TABLE 67 GCC COUNTRIES: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 144 TABLE 68 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 146 TABLE 69 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT), BY REGION, 2023–2031 (USD MILLION) 147 TABLE 70 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT), BY COUNTRY, 2023–2031 (USD MILLION) 147 TABLE 71 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT), BY COUNTRY, 2023–2031 (USD MILLION) 148 TABLE 72 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY REGION, 2023–2031 (USD MILLION) 149 TABLE 73 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023–2031 (USD MILLION) 149 TABLE 74 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023–2031 (USD MILLION) 149 TABLE 75 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023–2031 (USD MILLION) 150 TABLE 76 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023–2031 (USD MILLION) 150 TABLE 77 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY REGION, 2023–2031 (USD MILLION) 150 TABLE 78 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023–2031 (USD MILLION) 151 TABLE 79 HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY REGION, 2023–2031 (USD MILLION) 152 TABLE 80 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023–2031 (USD MILLION) 152 TABLE 81 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023–2031 (USD MILLION) 152 TABLE 82 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023–2031 (USD MILLION) 153 TABLE 83 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023–2031 (USD MILLION) 153 TABLE 84 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY REGION, 2023–2031 (USD MILLION) 153 TABLE 85 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023–2031 (USD MILLION) 154 TABLE 86 HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 156 TABLE 87 DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS FOR INFECTIOUS DISEASES 157 TABLE 88 HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2031 (USD MILLION) 158 TABLE 89 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 158 TABLE 90 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 159 TABLE 91 HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023–2031 (USD MILLION) 160 TABLE 92 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 160 TABLE 93 EUROPE: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 161 TABLE 94 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 161 TABLE 95 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 161 TABLE 96 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023–2031 (USD MILLION) 162 TABLE 97 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 162 TABLE 98 HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2031 (USD MILLION) 163 TABLE 99 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 163 TABLE 100 EUROPE: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 164 TABLE 101 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 164 TABLE 102 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 164 TABLE 103 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2031 (USD MILLION) 165 TABLE 104 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 165 TABLE 105 HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2023–2031 (USD MILLION) 166 TABLE 106 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 166 TABLE 107 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 167 TABLE 108 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 167 TABLE 109 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 167 TABLE 110 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2023–2031 (USD MILLION) 168 TABLE 111 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 168 TABLE 112 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 170 TABLE 113 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2031 (USD MILLION) 171 TABLE 114 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION) 171 TABLE 115 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION) 171 TABLE 116 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION) 172 TABLE 117 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION) 172 TABLE 118 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2031 (USD MILLION) 172 TABLE 119 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION) 173 TABLE 120 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2031 (USD MILLION) 174 TABLE 121 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION) 174 TABLE 122 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION) 175 TABLE 123 HUMAN MICROBIOME MANUFACTURING MARKET, BY SERVICE, 2023–2031 (USD MILLION) 177 TABLE 124 HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 181 TABLE 125 HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023–2031 (USD MILLION) 182 TABLE 126 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION) 182 TABLE 127 EUROPE: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION) 182 TABLE 128 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION) 183 TABLE 129 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION) 183 TABLE 130 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023–2031 (USD MILLION) 183 TABLE 131 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION) 184 TABLE 132 HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2031 (USD MILLION) 185 TABLE 133 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2031 (USD MILLION) 185 TABLE 134 EUROPE: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2031 (USD MILLION) 185 TABLE 135 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2031 (USD MILLION) 186 TABLE 136 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2031 (USD MILLION) 186 TABLE 137 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2031 (USD MILLION) 186 TABLE 138 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2031 (USD MILLION) 187 TABLE 139 HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY REGION, 2023–2031 (USD MILLION) 188 TABLE 140 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 188 TABLE 141 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 188 TABLE 142 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 189 TABLE 143 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 189 TABLE 144 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY REGION, 2023–2031 (USD MILLION) 189 TABLE 145 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 190 TABLE 146 HUMAN MICROBIOME MARKET, BY REGION, 2023–2031 (USD MILLION) 192 TABLE 147 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 193 TABLE 148 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 194 TABLE 149 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 194 TABLE 150 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 194 TABLE 151 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 195 TABLE 152 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 195 TABLE 153 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 195 TABLE 154 NORTH AMERICA: KEY MACROECONOMIC INDICATORS 196 TABLE 155 US: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 197 TABLE 156 US: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 197 TABLE 157 US: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 198 TABLE 158 US: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 198 TABLE 159 US: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 198 TABLE 160 US: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 199 TABLE 161 CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 199 TABLE 162 CANADA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 200 TABLE 163 CANADA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 200 TABLE 164 CANADA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 200 TABLE 165 CANADA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 201 TABLE 166 CANADA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 201 TABLE 167 EUROPE: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 202 TABLE 168 EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 202 TABLE 169 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 202 TABLE 170 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 203 TABLE 171 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 203 TABLE 172 EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 203 TABLE 173 EUROPE: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 204 TABLE 174 EUROPE: KEY MACROECONOMIC INDICATORS 205 TABLE 175 GERMANY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 206 TABLE 176 GERMANY: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 206 TABLE 177 GERMANY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 206 TABLE 178 GERMANY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 207 TABLE 179 GERMANY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 207 TABLE 180 GERMANY: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 207 TABLE 181 UK: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 208 TABLE 182 UK: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 209 TABLE 183 UK: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 209 TABLE 184 UK: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 209 TABLE 185 UK: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 210 TABLE 186 UK: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 210 TABLE 187 HUMAN MICROBIOME STARTUPS IN FRANCE 211 TABLE 188 FRANCE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 211 TABLE 189 FRANCE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 212 TABLE 190 FRANCE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 212 TABLE 191 FRANCE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 212 TABLE 192 FRANCE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 213 TABLE 193 FRANCE: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 213 TABLE 194 ITALY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 214 TABLE 195 ITALY: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 214 TABLE 196 ITALY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 215 TABLE 197 ITALY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 215 TABLE 198 ITALY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 215 TABLE 199 ITALY: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 216 TABLE 200 SPAIN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 217 TABLE 201 SPAIN: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 217 TABLE 202 SPAIN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 217 TABLE 203 SPAIN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 218 TABLE 204 SPAIN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 218 TABLE 205 SPAIN: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 218 TABLE 206 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 219 TABLE 207 REST OF EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 219 TABLE 208 REST OF EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 220 TABLE 209 REST OF EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 220 TABLE 210 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 220 TABLE 211 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 221 TABLE 212 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 223 TABLE 213 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 223 TABLE 214 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 223 TABLE 215 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 224 TABLE 216 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 224 TABLE 217 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 224 TABLE 218 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 225 TABLE 219 ASIA PACIFIC: MACROECONOMIC INDICATORS 225 TABLE 220 CHINA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 227 TABLE 221 CHINA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 227 TABLE 222 CHINA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 227 TABLE 223 CHINA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 228 TABLE 224 CHINA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 228 TABLE 225 CHINA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 228 TABLE 226 JAPAN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 229 TABLE 227 JAPAN: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 230 TABLE 228 JAPAN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 230 TABLE 229 JAPAN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 230 TABLE 230 JAPAN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 231 TABLE 231 JAPAN: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 231 TABLE 232 HUMAN MICROBIOME DIAGNOSTICS COMPANIES IN INDIA 232 TABLE 233 INDIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 232 TABLE 234 INDIA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 232 TABLE 235 INDIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 233 TABLE 236 INDIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 233 TABLE 237 INDIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 233 TABLE 238 INDIA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 234 TABLE 239 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 235 TABLE 240 SOUTH KOREA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 235 TABLE 241 SOUTH KOREA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 235 TABLE 242 SOUTH KOREA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 236 TABLE 243 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 236 TABLE 244 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 236 TABLE 245 AUSTRALIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 237 TABLE 246 AUSTRALIA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 238 TABLE 247 AUSTRALIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 238 TABLE 248 AUSTRALIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 238 TABLE 249 AUSTRALIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 239 TABLE 250 AUSTRALIA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 239 TABLE 251 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 240 TABLE 252 REST OF ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 240 TABLE 253 REST OF ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 240 TABLE 254 REST OF ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 241 TABLE 255 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 241 TABLE 256 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 241 TABLE 257 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 242 TABLE 258 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 242 TABLE 259 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 242 TABLE 260 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 243 TABLE 261 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 243 TABLE 262 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 243 TABLE 263 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 244 TABLE 264 LATIN AMERICA: KEY MACROECONOMIC INDICATORS 244 TABLE 265 BRAZIL: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 245 TABLE 266 BRAZIL: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 245 TABLE 267 BRAZIL: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 246 TABLE 268 BRAZIL: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 246 TABLE 269 BRAZIL: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 246 TABLE 270 BRAZIL: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 247 TABLE 271 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 247 TABLE 272 REST OF LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 248 TABLE 273 REST OF LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 248 TABLE 274 REST OF LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 248 TABLE 275 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 249 TABLE 276 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 249 TABLE 277 MIDDLE EAST: HUMAN MICROBIOME MARKET, BY REGION, 2023–2031 (USD MILLION) 250 TABLE 278 MIDDLE EAST: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 250 TABLE 279 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 250 TABLE 280 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 251 TABLE 281 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 251 TABLE 282 MIDDLE EAST: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 251 TABLE 283 MIDDLE EAST: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 252 TABLE 284 MIDDLE EAST: KEY MACROECONOMIC INDICATORS 252 TABLE 285 GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 253 TABLE 286 GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 253 TABLE 287 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 253 TABLE 288 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 254 TABLE 289 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 254 TABLE 290 GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 254 TABLE 291 GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 255 TABLE 292 SAUDI ARABIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 256 TABLE 293 SAUDI ARABIA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 256 TABLE 294 SAUDI ARABIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 256 TABLE 295 SAUDI ARABIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 257 TABLE 296 SAUDI ARABIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 257 TABLE 297 SAUDI ARABIA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 257 TABLE 298 UAE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 258 TABLE 299 UAE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 259 TABLE 300 UAE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 259 TABLE 301 UAE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 259 TABLE 302 UAE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 260 TABLE 303 UAE: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 260 TABLE 304 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 261 TABLE 305 REST OF GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 261 TABLE 306 REST OF GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 261 TABLE 307 REST OF GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 262 TABLE 308 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 262 TABLE 309 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 262 TABLE 310 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 263 TABLE 311 REST OF MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 264 TABLE 312 REST OF MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 264 TABLE 313 REST OF MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 264 TABLE 314 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 265 TABLE 315 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 265 TABLE 316 AFRICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 266 TABLE 317 AFRICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 266 TABLE 318 AFRICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 266 TABLE 319 AFRICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 267 TABLE 320 AFRICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 267 TABLE 321 AFRICA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 267 TABLE 322 AFRICA: KEY MACROECONOMIC INDICATORS 268 TABLE 323 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMAN MICROBIOME MARKET, JANUARY 2022–JULY 2025 269 TABLE 324 HUMAN MICROBIOME MARKET: DEGREE OF COMPETITION, 2024 274 TABLE 325 HUMAN MICROBIOME MARKET: REGION FOOTPRINT 282 TABLE 326 HUMAN MICROBIOME MARKET: DRUG & SUPPLEMENT FOOTPRINT 283 TABLE 327 HUMAN MICROBIOME MARKET: TYPE FOOTPRINT 284 TABLE 328 HUMAN MICROBIOME MARKET: DISEASE FOOTPRINT 285 TABLE 329 HUMAN MICROBIOME MARKET: DETAILED LIST OF KEY STARTUPS/SMES 288 TABLE 330 HUMAN MICROBIOME MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS 289 TABLE 331 HUMAN MICROBIOME MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025 290 TABLE 332 HUMAN MICROBIOME MARKET: DEALS, JANUARY 2022–JULY 2025 291 TABLE 333 HUMAN MICROBIOME MARKET: EXPANSIONS, JANUARY 2022–JULY 2025 292 TABLE 334 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY OVERVIEW 294 TABLE 335 INTERNATIONAL FLAVORS & FRAGRANCES INC.: PRODUCTS OFFERED 295 TABLE 336 INTERNATIONAL FLAVORS & FRAGRANCES INC.: DEALS, JANUARY 2022–JULY 2025 297 TABLE 337 INTERNATIONAL FLAVORS & FRAGRANCES INC.: EXPANSIONS, JANUARY 2022–JULY 2025 298 TABLE 338 SEED HEALTH, INC.: COMPANY OVERVIEW 300 TABLE 339 SEED HEALTH, INC.: PRODUCTS OFFERED 300 TABLE 340 SEED HEALTH, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025 301 TABLE 341 SEED HEALTH, INC.: DEALS, JANUARY 2022–JULY 2025 302 TABLE 342 SEED HEALTH, INC.: EXPANSIONS, JANUARY 2022−JULY 2025 302 TABLE 343 SERES THERAPEUTICS: COMPANY OVERVIEW 304 TABLE 344 SERES THERAPEUTICS: PRODUCTS OFFERED 305 TABLE 345 SERES THERAPEUTICS: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025 305 TABLE 346 SERES THERAPEUTICS: DEALS, JANUARY 2022–JULY 2025 306 TABLE 347 FERRING B.V.: COMPANY OVERVIEW 308 TABLE 348 FERRING B.V.: PRODUCTS OFFERED 309 TABLE 349 FERRING B.V.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025 310 TABLE 350 FERRING B.V.: DEALS, JANUARY 2022–JULY 2025 310 TABLE 351 PENDULUM: COMPANY OVERVIEW 312 TABLE 352 PENDULUM: PRODUCTS OFFERED 312 TABLE 353 PENDULUM: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025 313 TABLE 354 PENDULUM: DEALS, JANUARY 2022–JULY 2025 313 TABLE 355 OPTIBIOTIX HEALTH PLC: COMPANY OVERVIEW 315 TABLE 356 OPTIBIOTIX HEALTH PLC: PRODUCTS OFFERED 316 TABLE 357 OPTIBIOTIX HEALTH PLC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025 317 TABLE 358 OPTIBIOTIX HEALTH PLC: DEALS, JANUARY 2022–JULY 2025 318 TABLE 359 BIOGAIA: COMPANY OVERVIEW 319 TABLE 360 BIOGAIA: PRODUCTS OFFERED 320 TABLE 361 BIOGAIA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025 321 TABLE 362 BIOGAIA: DEALS, JANUARY 2022–JULY 2025 321 TABLE 363 BIOGAIA: EXPANSIONS, JANUARY 2022–JULY 2025 322 TABLE 364 MAAT PHARMA: COMPANY OVERVIEW 323 TABLE 365 MAAT PHARMA: PRODUCTS OFFERED 324 TABLE 366 MAAT PHARMA: DEALS, JANUARY 2022–JULY 2025 324 TABLE 367 MAAT PHARMA: OTHER DEVELOPMENTS, JANUARY 2022−JULY 2025 325 TABLE 368 MICROBA: COMPANY OVERVIEW 326 TABLE 369 MICROBA: PRODUCTS OFFERED 327 TABLE 370 MICROBA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025 327 TABLE 371 BIOMEBANK: COMPANY OVERVIEW 328 TABLE 372 BIOMEBANK: PRODUCTS OFFERED 328 TABLE 373 BIOMEBANK: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025 329 TABLE 374 BIOMEBANK: DEALS, JANUARY 2022–JULY 2025 329 TABLE 375 BIOMEBANK: EXPANSIONS, JANUARY 2022–JULY 2025 329 TABLE 376 BIOHM HEALTH: COMPANY OVERVIEW 330 TABLE 377 BIOHM HEALTH: PRODUCTS OFFERED 330 TABLE 378 BIOHM HEALTH: DEALS, JANUARY 2022–JULY 2025 332 TABLE 379 ACTIAL FARMACEUTICA SRL: COMPANY OVERVIEW 334 TABLE 380 ACTIAL FARMACEUTICA SRL: PRODUCTS OFFERED 334 TABLE 381 RESBIOTIC: COMPANY OVERVIEW 335 TABLE 382 RESBIOTIC: PRODUCTS OFFERED 335 TABLE 383 RESBIOTIC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025 336 TABLE 384 RESBIOTIC: DEALS, JANUARY 2022–JULY 2025 336 TABLE 385 RESBIOTIC: EXPANSIONS, JANUARY 2022–JULY 2025 337 TABLE 386 INFINANT HEALTH INC.: COMPANY OVERVIEW 338 TABLE 387 INFINANT HEALTH INC.: PRODUCTS OFFERED 338 TABLE 388 INFINANT HEALTH INC.: DEALS, JANUARY 2022–JULY 2025 339 TABLE 389 EXEGI PHARMA: COMPANY OVERVIEW 340 TABLE 390 EXEGI PHARMA: PRODUCTS OFFERED 340 TABLE 391 EXEGI PHARMA: DEALS, JANUARY 2022–JULY 2025 341 TABLE 392 FINCH THERAPEUTICS GROUP, INC.: COMPANY OVERVIEW 342 TABLE 393 FINCH THERAPEUTICS GROUP, INC.: PRODUCTS OFFERED 343 TABLE 394 FINCH THERAPEUTICS GROUP, INC.: DEALS, JANUARY 2022–JULY 2025 343 TABLE 395 INFANT BACTERIAL THERAPEUTICS AB: COMPANY OVERVIEW 344 TABLE 396 INFANT BACTERIAL THERAPEUTICS AB: PRODUCTS OFFERED 344 TABLE 397 VIOME LIFESCIENCES: COMPANY OVERVIEW 346 TABLE 398 VIOME LIFESCIENCES: PRODUCTS OFFERED 346 TABLE 399 VIOME LIFESCIENCES: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025 347 TABLE 400 GENOVA DIAGNOSTICS: COMPANY OVERVIEW 348 TABLE 401 GENOVA DIAGNOSTICS: PRODUCTS OFFERED 348 TABLE 402 AOBIOME: COMPANY OVERVIEW 349 TABLE 403 GUANGZHOU ZHIYI BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW 350 TABLE 404 NUBIYOTA: COMPANY OVERVIEW 351 TABLE 405 OXTHERA: COMPANY OVERVIEW 352 TABLE 406 NEXBIOME: COMPANY OVERVIEW 353 TABLE 407 VEDANTA BIOSCIENCES, INC.: COMPANY OVERVIEW 354 TABLE 408 ENTEROME: COMPANY OVERVIEW 355 TABLE 409 APSEN FARMACÊUTICA: COMPANY OVERVIEW 356 TABLE 410 METAGEN, INC.: COMPANY OVERVIEW 357 TABLE 411 SNIPR BIOME: COMPANY OVERVIEW 358 TABLE 412 MIKROBIOMIK: COMPANY OVERVIEW 359 TABLE 413 SYNLOGIC: COMPANY OVERVIEW 360 TABLE 414 GENETIC ANALYSIS: COMPANY OVERVIEW 361 TABLE 415 METABIOMICS: COMPANY OVERVIEW 361 TABLE 416 SUN GENOMICS, INC.: COMPANY OVERVIEW 362 FIGURE 1 HUMAN MICROBIOME MARKET SEGMENTATION AND REGIONAL SCOPE 35 FIGURE 2 RESEARCH DESIGN 38 FIGURE 3 HUMAN MICROBIOME MARKET: BREAKDOWN OF PRIMARIES 40 FIGURE 4 HUMAN MICROBIOME MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 41 FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2024 42 FIGURE 6 ILLUSTRATIVE EXAMPLE OF INTERNATIONAL FLAVORS & FRAGRANCES INC.: REVENUE SHARE ANALYSIS, 2024 42 FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 43 FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 44 FIGURE 9 HUMAN MICROBIOME MARKET: CAGR PROJECTIONS 46 FIGURE 10 DATA TRIANGULATION METHODOLOGY 47 FIGURE 11 HUMAN MICROBIOME MARKET, BY PRODUCT, 2025 VS. 2031 (USD MILLION) 49 FIGURE 12 HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2025 VS. 2031 (USD MILLION) 50 FIGURE 13 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2024 VS. 2030 (USD MILLION) 50 FIGURE 14 HUMAN MICROBIOME MARKET, BY DISEASE, 2025 VS. 2031 (USD MILLION) 51 FIGURE 15 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2031 (USD MILLION) 51 FIGURE 16 HUMAN MICROBIOME MARKET, BY END USER, 2024 VS. 2030 (USD MILLION) 52 FIGURE 17 HUMAN MICROBIOME MARKET: GEOGRAPHICAL SNAPSHOT 52 FIGURE 18 RISING DEMAND FOR PERSONALIZED MEDICINE AND ADVANCEMENTS IN MICROBIOME SEQUENCING TO DRIVE MARKET 54 FIGURE 19 US AND LIVE BACTERIA PRODUCTS (LBP) SEGMENT LED NORTH AMERICAN MARKET IN 2024 55 FIGURE 20 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT) SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 55 FIGURE 21 US TO DOMINATE GLOBAL MARKET DURING FORECAST PERIOD 56 FIGURE 22 HOSPITALS & CLINICS SEGMENT TO HOLD LARGEST MARKET SHARE IN 2025 56 FIGURE 23 HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 57 FIGURE 24 COMMERCIALIZATION ASPECTS OF MICROBIOMES FOR DRUGS VS. SUPPLEMENTS 63 FIGURE 25 HUMAN MICROBIOME MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 66 FIGURE 26 DISRUPTION INDEX: MARKET READINESS VS. ADOPTION VS. MATURITY 67 FIGURE 28 AVERAGE SELLING PRICE OF HUMAN MICROBIOME DRUGS, BY KEY PLAYER, 2024 (USD) 70 FIGURE 29 AVERAGE SELLING PRICE OF HUMAN MICROBIOME DIAGNOSTICS, BY KEY PLAYER, 2024 (USD) 70 FIGURE 30 AVERAGE SELLING PRICE TREND OF HUMAN MICROBIOME SUPPLEMENTS & DIAGNOSTICS, BY TYPE, 2022–2024 (USD) 73 FIGURE 31 AVERAGE SELLING PRICE OF HUMAN MICROBIOME SUPPLEMENTS, BY REGION, 2024 (USD) 74 FIGURE 32 VALUE CHAIN ANALYSIS FOR HUMAN MICROBIOME DRUGS 75 FIGURE 33 VALUE CHAIN ANALYSIS FOR HUMAN MICROBIOME SUPPLEMENTS 76 FIGURE 34 VALUE CHAIN ANALYSIS FOR HUMAN MICROBIOME DIAGNOSTICS 77 FIGURE 35 HUMAN MICROBIOME MARKET: ECOSYSTEM ANALYSIS 79 FIGURE 36 HUMAN MICROBIOME MARKET: INVESTMENT AND FUNDING SCENARIO, 2022–2024 82 FIGURE 37 HUMAN MICROBIOME MARKET: PATENT ANALYSIS, JANUARY 2014–DECEMBER 2024 92 FIGURE 38 REGULATORY LANDSCAPE OF LIVE BACTERIA PRODUCTS (LBP) 107 FIGURE 39 HUMAN MICROBIOME MARKET: PORTER’S FIVE FORCES ANALYSIS 108 FIGURE 40 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS 110 FIGURE 41 KEY BUYING CRITERIA, BY END USER 111 FIGURE 42 HUMAN MICROBIOME PIPELINE, BY DISEASE 112 FIGURE 43 HUMAN MICROBIOME PIPELINE, BY PHASE 113 FIGURE 44 HUMAN MICROBIOME PIPELINE, BY REGION 113 FIGURE 45 IMPACT OF AI/GEN AI ON HUMAN MICROBIOME MARKET 114 FIGURE 46 AI USE CASES 115 FIGURE 47 NORTH AMERICA: HUMAN MICROBIOME MARKET SNAPSHOT 193 FIGURE 48 ASIA PACIFIC: HUMAN MICROBIOME MARKET SNAPSHOT 222 FIGURE 49 REVENUE ANALYSIS OF KEY PLAYERS IN HUMAN MICROBIOME MARKET, 2022–2024 (USD MILLION) 272 FIGURE 50 MARKET SHARE ANALYSIS OF KEY PLAYERS IN HUMAN MICROBIOME MARKET, 2024 273 FIGURE 51 EV/EBITDA OF KEY PLAYERS 276 FIGURE 52 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY PLAYERS 276 FIGURE 53 HUMAN MICROBIOME MARKET: BRAND/PRODUCT COMPARISON 277 FIGURE 54 HUMAN MICROBIOME MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 280 FIGURE 55 HUMAN MICROBIOME MARKET: COMPANY FOOTPRINT 281 FIGURE 56 HUMAN MICROBIOME MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 287 FIGURE 57 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY SNAPSHOT (2024) 295 FIGURE 58 SERES THERAPEUTICS: COMPANY SNAPSHOT (2023) 304 FIGURE 59 FERRING B.V.: COMPANY SNAPSHOT (2024) 309 FIGURE 60 OPTIBIOTIX HEALTH PLC: COMPANY SNAPSHOT (2024) 316 FIGURE 61 BIOGAIA: COMPANY SNAPSHOT (2024) 320 FIGURE 62 MAAT PHARMA: COMPANY SNAPSHOT (2024) 323 FIGURE 63 MICROBA: COMPANY SNAPSHOT (2024) 326 FIGURE 64 FINCH THERAPEUTICS GROUP, INC.: COMPANY SNAPSHOT (2023) 342

Single User Licence	$4,950 USD
Multi User Licence	$6,650 USD
Corporate User Licence	$8,150 USD
Global User Licence	$10,000 USD

Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics, Diagnostics), Disease (Infectious, Gastrointestinal), Route (Oral, Rectal), CDMO (Formulation, Strain Engineering), Type (BCT/FMT, Live Bacteria) - Global Forecast to 2031

授權報價

報告摘要

同分類最新報告（醫療與生命科學）